Study of two targeted drugs for first-line KRAS G12C lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests two new drugs together (sosimerasib and IN10018) as a first treatment for people with a specific type of lung cancer that has the KRAS G12C gene change. The goal is to see if the combination works better than standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-squamous lung cancer (Stage IIIB/IIIC or IV) that can't be removed with surgery
- Your tumor has a change called KRAS G12C
- You have at least one tumor that can be measured on scans
- You are able to do daily activities (ECOG 0 or 1)
- You have not had a KRAS G12C inhibitor, FAK inhibitor, or pan-RAS inhibitor before
- If you could have children, you agree to use birth control during treatment and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (SKB264 and glecirasib) for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests two new targeted drugs (IN10018 and D-1553) together as a first treatment for advanced non-squamous lung cancer with a specific KRAS G12C mutation. It compares this combination to standard therapy to see if it works better.
This Phase 3 trial tests whether sotorasib plus standard chemotherapy works better than pembrolizumab (an immunotherapy) plus standard chemotherapy as first treatment for certain advanced lung cancers. It may help people whose tumors have a KRAS G12C mutation and that do not show PD-L1 on testing.
This trial tests a new targeted pill (olomorasib) combined with immunotherapy (pembrolizumab) and possibly chemotherapy for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and has not been treated before.
This trial tests an oral targeted drug called sotorasib for people with a specific type of advanced lung cancer (KRAS G12C mutation) who have not had any prior treatment for their advanced disease. It aims to see if this drug can shrink tumors and help patients without using standard chemotherapy or immunotherapy first.
This Phase 2 trial studies sotorasib, a targeted medicine, in people with non-small cell lung cancer (NSCLC) that has a specific KRAS mutation called G12C. You may be eligible if your cancer has spread or can’t be removed by surgery and has grown again after at least one previous treatment.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.